MedTrace Logo

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

NCT04669067 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-17

No results posted yet for this study

Summary

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.

Conditions

Interventions

DRUG

TL-895

TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

DRUG

KRT-232

KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

Sponsors & Collaborators

  • Kartos Therapeutics, Inc.

    collaborator INDUSTRY

  • Telios Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2024-11-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • France
  • Germany
  • Italy
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04669067 on ClinicalTrials.gov